Vaccination News Home Page

http://www.pediatrics.org/cgi/content/abstract/110/4/805

Full Text of this Article Reprint (PDF) Version of this Article P3Rs: Submit a response to this article Similar articles found in: Pediatrics Online PubMed PubMed Citation Search Medline for articles by: Pelton, S. I. || Klein, J. O. Alert me when: new articles cite this article   Download to Citation Manager

Collections under which this article appears: Infectious Disease & Immunity

PEDIATRICS Vol. 110 No. 4 October 2002, pp. 805-814

 

The Future of Pneumococcal Conjugate Vaccines for Prevention of Pneumococcal Diseases in Infants and Children

Stephen I. Pelton, MD and Jerome O. Klein, MD

From the Department of Pediatrics, Boston University School of Medicine, and Department of Pediatrics, Maxwell Finland Laboratory for Infectious Diseases, Boston Medical Center, Boston, Massachusetts

Seven-valent pneumococcal conjugate vaccine (PCV7) was licensed in February 2000. In June 2000, the Advisory Committee on Immunization Practices and the American Academy of Pediatrics recommended the universal administration of pneumococcal conjugate vaccine for all children 23 months of age and younger and for children 24 to 59 months of age who are at high risk for serious pneumococcal disease. Since then, >23 million doses have been administered in the United States. Postlicensure surveillance of invasive pneumococcal disease (IPD) in the United States from the Active Bacterial Core Surveillance program at the Centers for Disease Control and Prevention and the Northern California Kaiser Permanente Vaccine Study Center has reported a decline in IPD and in pneumococcal disease incidence as a result of vaccine serotypes, respectively. During this period, issues critical to the long-term success of PCV7 have become more relevant: Will PCV7 be as effective in groups of children who are at high risk for IPD as in healthy children? Will nonvaccine types replace vaccine serotypes in the nasopharynx and in disease? Why are the results of the clinical trials different for IPD and for acute otitis media? How many doses of PCV7 and what concentrations of antibody are necessary for protection? Will universal administration of PCV7 to children younger than 2 years reduce antimicrobial drug resistance and alter prescribing patterns of physicians for febrile infants? Have there been unanticipated adverse events or benefits observed? The purpose of this report is to review the current data available to address these questions and to identify gaps that will require additional knowledge to determine the ultimate value of pneumococcal conjugate vaccines in reducing the burden of pneumococcal disease in infants and children.

Key Words: pneumococcal disease • pneumococcal vaccine • conjugate vaccine • carriage • serotypes

Abbreviations: PCV, pneumococcal conjugate vaccine • IPD, invasive pneumococcal disease • NCKP, Northern California Kaiser Permanente • HIV, human immunodeficiency virus • NP, nasopharyngeal • PPV, pneumococcal polysaccharide vaccine • ELISA, enzyme-linked immunosorbent assay • OPA, opsonophagocytic activity • MnCC, meningococcal group C conjugate vaccine • Hib • Haemophilus influenzae type b • DTP, diphtheria-tetanus-pertussis

Received for publication Feb 1, 2002; accepted May 6, 2002.

Copyright © 2002 by the American Academy of Pediatrics. [Disclaimer]

Vaccination News Home Page

ALL INFORMATION, DATA, AND MATERIAL CONTAINED, PRESENTED, OR PROVIDED HERE IS FOR GENERAL INFORMATION PURPOSES ONLY AND IS NOT TO BE CONSTRUED AS REFLECTING THE KNOWLEDGE OR OPINIONS OF THE PUBLISHER, AND IS NOT TO BE CONSTRUED OR INTENDED AS PROVIDING MEDICAL OR LEGAL ADVICE.  THE DECISION WHETHER OR NOT TO VACCINATE IS AN IMPORTANT AND COMPLEX ISSUE AND SHOULD BE MADE BY YOU, AND YOU ALONE, IN CONSULTATION WITH YOUR HEALTH CARE PROVIDER.